Chemistry:UWA-001

From HandWiki
Revision as of 02:36, 6 February 2024 by John Stpola (talk | contribs) (linkage)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Chemical compound
UWA-001
UWA-001 structure.svg
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC16H17NO2
Molar mass255.317 g·mol−1
3D model (JSmol)

UWA-001 (also known as α-phenyl-MDMA and methylenedioxymephenidine) is a phenethylamine derivative invented at the University of Western Australia as non-toxic alternative to 3,4-methylenedioxy-N-methylamphetamine (MDMA) and researched as a potential treatment for Parkinson's disease.[1]

It has a 5-HT2A receptor affinity of 1.2 μM (~10-fold increase compared to MDMA), 1.3 μM for the serotonin transporter (~4-fold decrease compared to MDMA), 13.4 μM for the norepinephrine transporter (~26-fold increase compared to MDMA) and virtually no affinity for the dopamine transporter (>50 μM).[1]

Unlike MDMA and para-methoxyamphetamine (but similarly to ketamine),[2] UWA-001 increases prepulse inhibition and was therefore considered to be non-psychoactive, though it was not assayed at other binding sites.[3] It is toxic to the SH-SY5Y cell line at high concentrations, however significantly less toxic than MDMA at all concentrations tested.[3]

UWA-001 is structurally related to the diarylethylamines lefetamine (a stimulant and opioid) and the dissociative anesthetic ephenidine, which acts as a NMDA receptor antagonist.

See also

References

  1. 1.0 1.1 "A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates". FASEB Journal 26 (5): 2154–63. May 2012. doi:10.1096/fj.11-195016. PMID 22345403. 
  2. "Low dose ketamine increases prepulse inhibition in healthy men". Neuropharmacology 44 (6): 729–37. May 2003. doi:10.1016/S0028-3908(03)00073-X. PMID 12681371. 
  3. 3.0 3.1 "Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity.". MedChemComm 1 (4): 287–93. 2010. doi:10.1039/C0MD00108B.